[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypereosinophilic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypereosinophilic-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,74,97,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100552789","phase-2-dupilumab-as-add-on-therapy-for-hypereosinophilic-syndrome-with-partial-clinical-response-to-eosinophil-depleting-biologic-agents-100552789",false,"NCT06477653","Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents","A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n1. Age \\>=18 years\n2. Documented diagnosis of HES with historic AEC\\>1.5x10\\^9\u002FL on two occasions, no secondary etiology for the eosinophilia despite careful clinical evaluation, and evidence of end organ damage (histologic evidence of tissue infiltration by eosinophils and\u002For objective evidence of clinical pathology in any organ system that is temporally associated with eosinophilia and not clearly attributable to another cause)\n3. Currently receiving treatment with an eosinophil-lowering biologic (mepolizumab, reslizumab, or benralizumab) for a minimum of 24 weeks\n4. AEC\\\u003C0.5x10\\^9\u002FL\n5. Residual symptoms after a minimum of 24 weeks of eosinophil-lowering biologic therapy with at least 1 most bothersome symptom of moderate severity (HES-SI score \\>=2) consistent with \\>=1 of the following diagnoses:\n\n   a. asthma, defined as physician-documented asthma requiring medium to high dose inhaled corticosteroids + long-acting beta agonist b. atopic dermatitis, defined as physician-documented chronic or recurrent inflammatory skin disease\n\n   c. CRSwNP, defined as evidence of rhinosinusitis and nasal polyposis on physical examination or imaging\n\n   d. EoE, defined as biopsy-proven esophageal eosinophilia \\>15 eosinophils\u002Fhigh power field\n6. For participants who can become pregnant: sexual abstinence or use of highly effective contraception (i.e., partner vasectomy, bilateral tubal ligation, IUD, progestin implants, and other hormonal methods) starting 4 weeks prior to study drug initiation and agreement to use such a method during study participation and for an additional 12 weeks after the end of study drug administration\n7. Participation in NIH protocol 94-I-0079 (Activation and function of eosinophils in conditions with blood or tissue eosinophilia)\n8. Ability of subject to understand and the willingness to sign a written informed consent document\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnancy or lactation\n2. Known allergic reaction to dupilumab or any of the excipients in Dupixent(TM)\n3. Febrile illness within 7 days of enrollment\n4. Treatment with an investigational drug or other intervention other than mepolizumab, reslizumab, or benralizumab within 12 weeks or 4 half-lives of the investigational agent (whichever is longer).\n5. Known or suspected acquired or inborn immunodeficiency disorder, including HIV infection\n6. Known diagnosis of eosinophilic granulomatosis with polyangiitis\n7. Change in eosinophil-active therapy within the past 6 weeks, including but not limited to topical corticosteroids, leukotriene inhibitors, initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food (in patients with gastrointestinal involvement), and proton pump inhibitors (in patients with gastrointestinal involvement)\n8. Planned or anticipated major surgical procedure during the study\n9. Active parasitic infection\n10. History of malignancy within 5 years, excluding completely treated in situ carcinoma of the cervix, or squamous or basal cell carcinoma of the skin\n11. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study\n\nFor patients with eosinophilic gastrointestinal disease only:\n\n1. Active infection with Helicobacter pylori\n2. History of achalasia, Crohn s disease, ulcerative colitis, celiac disease, or prior esophageal surgery\n3. Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to 10 mm upper endoscope","ALL","18 Years","99 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nHypereosinophilic syndrome (HES) is a blood disorder that causes high levels of white blood cells called eosinophils. HES can damage the lungs and airways, intestines, skin, and other organs. The current primary treatment for HES can cause serious side effects. Secondary treatments do not work in all people.\n\nObjective:\n\nTo test an approved drug (dupilumab), combined with other drugs, in people with HES.\n\nEligibility:\n\nPeople aged 18 years and older who take drugs (mepolizumab, reslizumab, or benralizumab) to treat HES.\n\nDesign:\n\nParticipants will have up to 6 clinic visits and 7 remote visits in up to 48 weeks.\n\nParticipants will be screened. They will have blood and urine tests. They will have a test of their heart function. They will take surveys about how HES affects their daily life. Some participants may have a bone marrow biopsy: A sample of tissue and fluid from inside a bone will be removed with a large needle.\n\nParticipants will have other tests specific to their symptoms. For example, those with symptoms affecting their lungs will have breathing tests. Others may have tests that target symptoms in their sinuses, gastrointestinal tract, or skin.\n\nDupilumab is injected under the skin once every 1 or 2 weeks. Dose and timing will vary among participants. They will be taught how to inject themselves at home between clinic visits. They will take dupilumab plus their current medications for 24 weeks. If the drug is helping them, they will continue taking it for another 24 weeks.\n\nParticipants will have a final visit 12 weeks after their last dose.",[27],"Hypereosinophilic Syndrome",[27,29,30,31,32],"Eosinophil","Monoclonal Antibody","Clinical Trial","Treatment","RECRUITING","2026-05-08",{"date":36,"type":37},"2026-05-11","ACTUAL",{"date":39,"type":37},"2025-02-05",{"date":41,"type":21},"2027-03-30",{"name":43,"class":44},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":4,"leadSponsor":73,"locationsCount":45},"100064634","a-longitudinal-study-of-familial-hypereosinophilia-fe-natural-history-and-markers-of-disease-progression-100064634","NCT00091871","A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 1-100 years of age\n* Genetically related member of a previously identified family with FE\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Any condition that the investigator feels put the subject at unacceptable risk for participation in the study\n* Pregnancy (in family members who do not have eosinophilia)",true,"1 Year","100 Years",{"count":56,"type":21},50,"OBSERVATIONAL","Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies.\n\nThis study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities). It will enroll approximately 50 individuals (both adults and children) from a previously studied family with FE. This is a long-term study of indefinite duration.\n\nParticipants will undergo yearly clinical examinations including medical history, physical examination, bloodwork, EKG, echocardiogram, and pulmonary function tests, with additional or more frequent examinations and tests as required. In addition, participants will donate blood and tissue for research purposes. Both adult and child participants will donate blood. At the initial evaluation, adult participants will donate bone marrow. During the study, some adult participants will also undergo a limited number of leukaopheresis sessions, in which blood is donated from one arm, the blood is separated into red blood cells and other components, and the red blood cells are returned into the donor's other arm.",[60,27],"Eosinophilia",[62,29,63,64,65,66,67],"Hypereosinophilia","Familial","Interleukin 5","Natural History","Familial Hypereosinophilia","FE","2026-05-06",{"date":70,"type":37},"2026-05-07",{"date":72,"type":37},"2005-06-08",{"name":43,"class":44},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100363892","natural-history-of-hypereosinophilia-and-hypereosinophilic-syndromes-100363892","NCT04018118","Natural History of Hypereosinophilia and Hypereosinophilic Syndromes","Study of Clinical Profiles of Patients Followed for Chronic Hypereosinophilia and\u002For Hypereosinophilic Syndrome by the Creation of a National Cohort","COHESION","Inclusion Criteria:\n\n* Men or Women of any age :\n* With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO)\n* With an AEC \\> 1500\u002Fmm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic)\n* HES diagnosis since 2005\u002F01\u002F01\n* Patients socially insured\n* Patient who agreed to participate to the study, its proceedings and duration.\n\nExclusion Criteria:\n\n* Known HIV infection\n* Not socially insured\n* Person unable to receive a enlighten information\n* Person who refuse to sign the consent\n* Persons deprived of their liberty\n* Persons benefiting from a system of legal protection (tutelage \u002F guardianship)",{"count":83,"type":21},600,"Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments.\n\nUnderlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE\u002FHES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE\u002FHES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)",[60,27],[60,62,27],"2026-02-18",{"date":89,"type":37},"2026-02-20",{"date":91,"type":37},"2019-05-06",{"date":93,"type":21},"2031-05",{"name":95,"class":96},"University Hospital, Lille","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100347260","phase-2-ruxolitinib-in-treating-patients-with-hypereosinophilic-syndrome-or-primary-eosinophilic-disorders-100347260","NCT03801434","Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders","Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders","Inclusion Criteria:\n\n* Subject with idiopathic hypereosinophilic syndrome must meet the following:\n\n  * Has as at least 2 readings with an absolute eosinophil count \\>= 1,500\u002Fmm\\^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).\n  * Dependent, intolerant or refractory to corticosteroids OR has relapsed\u002Frefractory disease to other therapy besides corticosteroids.\n  * Symptomatic from his\u002Fher disease OR has one or more signs of organ damage (assessed by the investigator as possibly-related to eosinophilia or biopsy-proven). This can include skin, lung, cardiac, central nervous system, liver, or gastrointestinal (GI) involvement, or evidence of symptomatic hepatic or splenic enlargement.\n* Subject with lymphocyte-variant hypereosinophilia must meet the following\n\n  * Has at least 2 readings with an absolute eosinophil count \\>= 1,500\u002Fmm\\^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).\n  * Dependent, intolerant or refractory to corticosteroids\\* OR has relapsed\u002Frefractory disease to other therapy besides corticosteroids.\n  * Symptomatic from his\u002Fher disease OR has one or more signs of organ damage (assessed by the investigator as possibly-related to eosinophilia or biopsy-proven). This can include skin, lung, cardiac, central nervous system, liver, or GI involvement, or evidence of symptomatic hepatic or splenic enlargement\n  * Has abnormal T-lymphocyte immuno-phenotype by flow cytometry.\n* Subject with chronic eosinophilic leukemia, not otherwise specified (CEL,NOS) must meet the following\n\n  * Has at least 2 readings with an absolute eosinophil count \\>= 500\u002Fmm\\^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).\n  * Newly-diagnosed OR receiving corticosteroids OR has relapsed\u002Frefractory disease to any therapy besides corticosteroids.\n  * Has increased blasts in the blood or bone marrow (\\> 5% and \\\u003C 20%), and\u002For a clonal cytogenetic or molecular abnormality\n\n    * Subjects with JAK2 mutations are included within this group.\n* Subject with JAK2-rearranged eosinophilic neoplasm must meet the following\n\n  * Has at least 2 readings with an absolute eosinophil count \\>= 500\u002Fmm\\^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).\n  * Newly-diagnosed OR receiving corticosteroids OR has relapsed\u002Frefractory disease to any therapy besides corticosteroids.\n\n    * This group includes subjects with PCM1-JAK2, BCR-JAK2, ETV6-JAK2 or other JAK2 rearrangements.\n* If receiving corticosteroids, must be a stable dose for \\>= 28 days prior to Day 1 (unstable dosing not eligible).\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 3.\n* Willing and able to review and execute informed consent (legally-authorized consent acceptable).\n\nExclusion Criteria:\n\n* Active life-threatening complication(s) from underlying eosinophilic disease (i.e., leukostasis; acute thromboembolic disease including central nervous system (CNS) involvement; severe pulmonary or cardiac dysfunction). Stabilization of acute, life-threatening eosinophil-related co-morbidities will allow enrollment of the patient.\n* World Health Organization (WHO)-defined myeloid neoplasm associated with eosinophilia other than CEL NOS and JAK2 rearranged neoplasms (e.g., myelodysplastic syndrome (MDS); myeloproliferative neoplasms (MPN); MDS\u002FMPN overlap disorders; and systemic mastocytosis (SM).\n* Reactive hypereosinophilia due to connective tissue disease, sarcoidosis or eosinophilic granulomatosis with polyangiitis.\n* Organ-restricted ?tissue? eosinophilia with the absence of peripheral eosinophilia in the blood.\n* Invasive malignancy over the previous 2 years except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers.\n* Myeloid or lymphoid neoplasm with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.\n* Anticipated to receive a hematopoietic stem cell transplant within the first 6 months of treatment on trial.\n* Major surgery within 4 weeks prior to entering the study.\n* Life expectancy of \\\u003C 6 months.\n* Known diagnosis of human immunodeficiency virus (HIV).\n* Known diagnosis of chronic active hepatitis B or C (viral testing is not required). Subjects with a known history of hepatitis B and\u002For C are allowed on trial if at the time of enrollment, the virus is not active and undetected (testing required if there is a known history), and such patients are not actively receiving antiviral treatment specific for hepatitis B and\u002For C.\n* Clinically serious infections requiring ongoing antibiotic therapy.\n* Parasitic infection diagnosed within 24 weeks prior to enrollment.\n* Platelet count =\\\u003C 25 x 10\\^9\u002FL at baseline.\n* Alanine aminotransferase (ALT)\u002Fserum glutamate pyruvate transaminase (SGPT) \\> 4 x upper limit of normal (ULN) or direct bilirubin \\> 4 x ULN (if considered to be unrelated to the underlying eosinophilic disorder).\n* End-stage renal function (creatinine clearance \\[CrCl\\] \\\u003C 15 mL\u002Fmin or glomerular filtration rate \\[GFR\\] \\\u003C 15 mL\u002Fmin) regardless of whether hemodialysis is required.\n* Use of investigational or commercial therapies with the intent to treat the underlying eosinophilic disorder within 28 days of study start, including interferon; imatinib; alemtuzumab; cyclosporine; methotrexate; mepolizumab; benralizumab; or other antibody therapies.\n* Use of hydroxyurea within 7 days of study start.\n* Prior therapy with ruxolitinib or other JAK inhibitors.\n* Previous allergic reactions to JAK inhibitors or excipients.\n* Unwilling to commit to abstinence from heterosexual contact or agree to use and comply with highly effective contraception, 28 days prior to starting study drug, during the treatment period and for 12 weeks after discontinuation of study treatment.\n* Females of childbearing potential who have a positive pregnancy test (urine or serum) during screening period.",{"count":105,"type":21},10,[24],"This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.",[109,110,111,112,113,114,60,115,27,116,117,118],"BCR-JAK2 Fusion Protein Expression","Blasts 20 Percent or Less of Peripheral Blood White Cells","Blasts More Than 5 Percent of Bone Marrow Nucleated Cells","Blasts More Than 5 Percent of Peripheral Blood White Cells","Blasts Under 20 Percent of Bone Marrow Nucleated Cells","Chronic Eosinophilic Leukemia, Not Otherwise Specified","Hepatomegaly","JAK2 Gene Mutation","Splenomegaly","TEL-JAK2 Fusion Protein Expression","2025-12-20",{"date":121,"type":37},"2025-12-23",{"date":123,"type":37},"2019-11-15",{"date":125,"type":21},"2028-12-30",{"name":127,"class":96},"William Shomali",4,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":157},"100464951","phase-3-depemokimab-in-participants-with-hypereosinophilic-syndrome-efficacy-and-safety-trial-100464951","NCT05334368","Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial","A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)","DESTINY","Inclusion Criteria:\n\n* Participants who are greater than or equal (\\>=) 40 kilogram (kg) at Screening Visit 1.\n* Participants who have a documented diagnosis of HES prior to Visit 2.\n* A history of 2 or more HES flares within the past 12 months prior to Visit 1.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: a) woman of non-childbearing potential (WONCBP) Or b) woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\\\u003C) 1 percentage (%).\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Participants with HES disease manifestations which in the opinion of the investigator may put the participant at unacceptable risk from study participation or confound interpretation of efficacy or safety data.\n* Participants with chronic or ongoing active infections requiring systemic treatment or a pre-existing parasitic infestation within 6 months prior to Visit 1.\n* Participants with a known immunodeficiency (e.g., Human Immunodeficiency Virus \\[HIV\\]), other than that explained by the use of OCS or other therapy taken for HES.\n* Participants with a history of or current lymphoma.\n* Participants with current malignancy or previous history of cancer in remission for less than 5 years prior to Visit 1. Participants that had localized carcinoma (i.e., basal or squamous cell) of the skin which was resected for cure will not be excluded.\n* Participants with a haematologic malignancy with hypereosinophilia in which HES is not the primary diagnosis, e.g., chronic myeloid leukaemia, myelodysplastic syndrome, chronic eosinophilic leukaemia-not otherwise specified.\n* Cirrhosis or current unstable liver or biliary disease per investigator assessment.\n* Participants who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment.\n* Participants with current diagnosis of vasculitis.\n* Hypereosinophila with no clinical symptoms and\u002For proof of organ dysfunction.\n* Clinical diagnosis of Eosinophilic granulomatosis with polyangiitis (EGPA).\n* Participants with an allergy\u002F intolerance to a monoclonal antibody or biologic, or any of the excipients of the investigational product.\n* Participants who have a previous documented failure with anti-interleukin (IL)-5\u002F5R therapy.\n* Participants who have received monoclonal antibodies (mAb) within 30 days or 5 half-lives, whichever is longer, prior to Visit 1.\n* Participants who test positive for the FIP1L1-PDGFRα fusion gene.\n* QT interval corrected for heart rate according to Fridericia's formula (QTcF) ≥450 milliseconds (msec) or QTcF ≥480 msec for participants with Bundle Branch Block at Screening Visit 1.\n* Participants who are not responsive to OCS based on clinical response or blood eosinophil counts in the opinion of the Investigator.\n* Participants who are pregnant or breastfeeding.",{"count":138,"type":21},123,[140],"PHASE3","This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.\n\nThe study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells\u002F microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy.\n\nParticipants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.",[27],[144,27,135,145,146],"Depemokimab","Monoclonal antibody","Anti-interleukin -5","2025-11-24",{"date":149,"type":37},"2025-11-25",{"date":151,"type":37},"2022-09-06",{"date":153,"type":21},"2028-12-19",{"name":155,"class":156},"GlaxoSmithKline","INDUSTRY",91]